Merck & Co. will acquire Peloton Therapeutics Inc. for as much as $2.2 billion in cash and additional payments, making the deal just a single day before the closely held developer of cancer therapies was to begin trading on the stock market.
Merck will pay $1.05 billion in cash, plus $1.15 billion in additional payments based on how the small company’s experimental drugs fare as they are developed further by Merck, the firms said in a statement announcing the deal Tuesday.
The deal offers an immediate payout for Peloton’s investors, including Dallas-based venture capital firm Remeditex Ventures and San Francisco’s The Column Group. At the $17 high range of Peloton’s expected initial public offering, the market would have valued the company at $756 million. If Peloton earns all of the future payouts in the deal, Merck will have paid the equivalent of almost $50 a share.
Peloton is focused on development of treatments targeting a pathway that’s activated by low levels of oxygen, according to a statement from the companies, and its lead experimental drug is aimed at kidney cancer.
Drugmakers around the world are shopping for new treatments for cancer, one of the hottest markets in the pharma industry with about $133 billion in global sales. Merck sells Keytruda, a mega-blockbuster drug that helps turn the immune system against cancer cells. It has been shopping for new therapies that will diversify its offerings, and Chief Executive Officer Ken Frazier said during an April conference call that the company would be looking for small to mid-size deals.
Peloton, which is based in Dallas, had said earlier this month that it was planning to raise up to $159.4 million in an initial public offering. That offering was set to begin trading publicly on Wednesday.
The companies see the transaction closing in the third quarter of the year. Merck is represented by Credit Suisse as financial adviser, and Peloton is represented by Centerview Partners.
Merck shares were up 0.8% to $79.49 at 10:38 a.m. in New York.
(Updates Merck shares in final paragraph.)
To contact the reporters on this story: Nick Lichtenberg in New York at email@example.com;John Lauerman in London at firstname.lastname@example.org
To contact the editors responsible for this story: Drew Armstrong at email@example.com, Cécile Daurat
©2019 Bloomberg L.P.